Summary
On September 18, 2025, BioCardia (NASDAQ: BCDA) announced top-line data from the roll-in cohort of the CardiAMP Chronic Myocardial Ischemia Trial. At the six-month primary follow-up, CardiAMP Cell Therapy was:
・Well tolerated by patients.
・Associated with significant improvements in exercise tolerance.
・Led to a reduction in angina episodes.
These results highlight the potential of CardiAMP Cell Therapy to address unmet medical needs in patients with chronic myocardial ischemia and refractory angina, strengthening BioCardia’s position in the cardiovascular therapeutics market.
Phase3bと同時に実施しているCardiAMP慢性心筋虚血（Chronic Myocardial Ischemia）のPhase 2試験（6か月データの速報）は良好🍵
最新結果（2025年9月18日発表）
・治療は良好に忍容
・運動耐容能が有意に改善
・狭心症発作が減少
・意義：標準治療で効果が得られない治療抵抗性狭心症に新しい選択肢を提供できる可能性
Summary
On September 18, 2025, BioCardia (NASDAQ: BCDA) announced top-line data from the roll-in cohort of the CardiAMP Chronic Myocardial Ischemia Trial. At the six-month primary follow-up, CardiAMP Cell Therapy was:
・Well tolerated by patients.
・Associated with significant improvements in exercise tolerance.
・Led to a reduction in angina episodes.
These results highlight the potential of CardiAMP Cell Therapy to address unmet medical needs in patients with chronic myocardial ischemia and refractory angina, strengthening BioCardia’s position in the cardiovascular therapeutics market.
投資の参考になりましたか？